Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C28H30N2O6 |
| Molecular Weight | 490.5476 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@@H](OC1=CC=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=CC=CC=C4O3)=C1)C(O)=O
InChI
InChIKey=ZHKNLJLMDFQVHJ-RUZDIDTESA-N
InChI=1S/C28H30N2O6/c1-3-25(27(31)32)35-23-9-6-8-20(18-23)19-30(28-29-24-10-4-5-11-26(24)36-28)16-7-17-34-22-14-12-21(33-2)13-15-22/h4-6,8-15,18,25H,3,7,16-17,19H2,1-2H3,(H,31,32)/t25-/m1/s1
Pemafibrate (Parmodia®) is a novel, highly selective peroxisome proliferator-activated receptor (PPAR)-α modulator (SPPARM). It acts by binding to PPAR-α and regulating the expression of target genes that modulate lipid metabolism, thereby decreasing plasma triglyceride levels and increasing high-density lipoprotein cholesterol levels. Developed by Kowa Company, Ltd., oral pemafibrate has been approved in Japan for the treatment of hyperlipidaemia (including familial hyperlipidaemia). Pemafibrate is undergoing phase III development in a
number of countries for the treatment of dyslipidaemias
and is also in phase III development for the treatment of
hypertriglyceridaemia.
Approval Year
Sample Use Guides
The recommended
dosage of oral pemafibrate is 0.1 mg twice daily
(administered in the morning and evening); this dosage can
be adjusted according to age and symptoms to a maximum
dosage of 0.2 mg twice daily.
Route of Administration:
Oral
In Vitro Use Guide
Curator's Comment: To test for a direct effect on apoB secretion by intestinal epithelial cells, polarized
Caco-2/TC7 cells grown and polarized on a porous filter to mimic the human
intestinal barrier, were treated with the different PPARα ligands added to the apical
side. After 24 hours, medium in the basolateral compartment was collected,
chylomicrons isolated by centrifugation and apoB quantified by ELISA.
Pemafibrate (K-877) (10uM) significantly decreased apoB
secretion.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
934223
Created by
admin on Fri Dec 15 21:32:10 GMT 2023 , Edited by admin on Fri Dec 15 21:32:10 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C166474
Created by
admin on Fri Dec 15 21:32:10 GMT 2023 , Edited by admin on Fri Dec 15 21:32:10 GMT 2023
|
PRIMARY | |||
|
5248
Created by
admin on Fri Dec 15 21:32:10 GMT 2023 , Edited by admin on Fri Dec 15 21:32:10 GMT 2023
|
PRIMARY | |||
|
848259-27-8
Created by
admin on Fri Dec 15 21:32:10 GMT 2023 , Edited by admin on Fri Dec 15 21:32:10 GMT 2023
|
PRIMARY | |||
|
Pemafibrate
Created by
admin on Fri Dec 15 21:32:10 GMT 2023 , Edited by admin on Fri Dec 15 21:32:10 GMT 2023
|
PRIMARY | |||
|
9692
Created by
admin on Fri Dec 15 21:32:10 GMT 2023 , Edited by admin on Fri Dec 15 21:32:10 GMT 2023
|
PRIMARY | |||
|
100000174784
Created by
admin on Fri Dec 15 21:32:10 GMT 2023 , Edited by admin on Fri Dec 15 21:32:10 GMT 2023
|
PRIMARY | |||
|
11526038
Created by
admin on Fri Dec 15 21:32:10 GMT 2023 , Edited by admin on Fri Dec 15 21:32:10 GMT 2023
|
PRIMARY | |||
|
m12073
Created by
admin on Fri Dec 15 21:32:10 GMT 2023 , Edited by admin on Fri Dec 15 21:32:10 GMT 2023
|
PRIMARY | |||
|
DTXSID00233891
Created by
admin on Fri Dec 15 21:32:10 GMT 2023 , Edited by admin on Fri Dec 15 21:32:10 GMT 2023
|
PRIMARY | |||
|
17VGG92R23
Created by
admin on Fri Dec 15 21:32:10 GMT 2023 , Edited by admin on Fri Dec 15 21:32:10 GMT 2023
|
PRIMARY | |||
|
DB15212
Created by
admin on Fri Dec 15 21:32:10 GMT 2023 , Edited by admin on Fri Dec 15 21:32:10 GMT 2023
|
PRIMARY | |||
|
CHEMBL3545412
Created by
admin on Fri Dec 15 21:32:10 GMT 2023 , Edited by admin on Fri Dec 15 21:32:10 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
